Compare

Corbus Pharmaceuticals Holdings, Inc./$CRBP

1D1W1M3M6MYTD1Y5YMAX

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Ticker
$CRBP
Sector
Health
Primary listing
NASDAQ
Employees
36

CRBP Metrics

BasicAdvanced
$55M
-
-$6.09
2.64
-

What the Analysts think about CRBP

Analyst ratings (Buy, Hold, Sell) for Corbus Pharmaceuticals Holdings, Inc. stock.
Analyst projections of the future price of Corbus Pharmaceuticals Holdings, Inc. stock.

CRBP Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

CRBP Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing CRBP

Funds
Fund name
Fund size
$CRBP weighting
SPDR Russell 2000 US Small Cap€R2US
$5.3B0.00%
SPDR Russell 2000 US Small Cap£R2SC
$5.3B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.